share_log

Aditxt | CORRESP: CORRESP

Aditxt | CORRESP: CORRESP

Aditxt | CORRESP:信函
美股SEC公告 ·  2024/02/14 11:41

Moomoo AI 已提取核心信息

Aditxt, Inc., a biotech company, has responded to a comment from the U.S. Securities and Exchange Commission (SEC) regarding its Registration Statement on Form S-1, initially filed on January 25, 2024. The SEC's inquiry, dated February 12, 2024, pertained to Aditxt's proposed merger with Evofem Biosciences, Inc., and the acquisition of assets from MDNA Life Sciences, Inc., and Brain Scientific, Inc. Aditxt entered into a merger agreement with Evofem on December 11, 2023, which is pending approval from shareholders and the effectiveness of a registration statement on Form S-4. The SEC requested additional information on pro forma financial statements and financial statements of Evofem, as well as clarification on whether the acquisitions of MDNA and Brain Scientific assets required similar disclosures. Aditxt clarified...Show More
Aditxt, Inc., a biotech company, has responded to a comment from the U.S. Securities and Exchange Commission (SEC) regarding its Registration Statement on Form S-1, initially filed on January 25, 2024. The SEC's inquiry, dated February 12, 2024, pertained to Aditxt's proposed merger with Evofem Biosciences, Inc., and the acquisition of assets from MDNA Life Sciences, Inc., and Brain Scientific, Inc. Aditxt entered into a merger agreement with Evofem on December 11, 2023, which is pending approval from shareholders and the effectiveness of a registration statement on Form S-4. The SEC requested additional information on pro forma financial statements and financial statements of Evofem, as well as clarification on whether the acquisitions of MDNA and Brain Scientific assets required similar disclosures. Aditxt clarified that the merger with Evofem is not yet deemed probable due to conditions beyond its control and cannot assure the provision of a previously agreed loan to Evofem. The company also stated that the assets acquired from MDNA and Brain Scientific do not constitute a business under SEC rules and do not require pro forma information as they are not revenue-producing and did not include facilities, customers, or operating rights. Aditxt has revised its disclosure in Amendment No. 2 to the Registration Statement to comply with the SEC's disclosure requirements and included updates on its recent Form 8-K filings.
生物科技公司Aditxt已回应美国证券交易委员会(SEC)就其于2024年1月25日最初提交的S-1表格的注册声明进行的评论。SEC于2024年2月12日发出的问询涉及Aditxt与Evofem Biosciences公司的拟议合并以及从MDNA Life Sciences公司和Brain Scientific公司收购资产。Aditxt于2023年12月11日与Evofem签署了合并协议,该协议待股东批准以及S-4表格的有效性。SEC要求提供关于影子财务报表和Evofem的财务报表的额外信息,以及是否需要类似的披露,证明MDNA和Brain Scientific资产的收购。Aditxt澄清称,...展开全部
生物科技公司Aditxt已回应美国证券交易委员会(SEC)就其于2024年1月25日最初提交的S-1表格的注册声明进行的评论。SEC于2024年2月12日发出的问询涉及Aditxt与Evofem Biosciences公司的拟议合并以及从MDNA Life Sciences公司和Brain Scientific公司收购资产。Aditxt于2023年12月11日与Evofem签署了合并协议,该协议待股东批准以及S-4表格的有效性。SEC要求提供关于影子财务报表和Evofem的财务报表的额外信息,以及是否需要类似的披露,证明MDNA和Brain Scientific资产的收购。Aditxt澄清称,与Evofem的合并尚未被认为是可能的,原因是有超出其控制范围的条件,并且不能保证向Evofem提供先前达成的贷款。公司还表示,从MDNA和Brain Scientific获得的资产不符合SEC规则中对业务的定义,不需要影子财务报表,因为它们不产生收入,并未包括设施、客户或营业权。Aditxt已修订了在注册声明的第2版上的披露内容,以符合SEC的披露要求,并包括其最近提交的8-k表格的更新。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息